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Yasuyuki Okuma10, Yutaka Machida11, Hideto Miwa11, Chikako Suzuki12, Asuka Kazama13, Masahiko Tomiyama14,
Takeshi Kihara15, Motoyuki Hirasawa16, Hideki Shimura17 and Nobutaka Hattori2Erratum
After publication of the original article [1], it came to
the authors’ attention that there was an error in the
number of male and female participants. The correct
number is 90 male and 88 female, not 89 male and 89
female as originally reported.
This error was present in the Methods section of the
abstract and in Table 1.
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Table 1 The baseline characteristics of the study participants
Mean Std. Deviation
Age 64.2 9.2
Disease duration 6.8 4.5
Sex (male/female) n 90 88
Wearing off (+/−) n 58 120
Dyskinesia (+/−) n 42 136
Levodopa mg 344.1 202.8
Levodopa (+/−) n 154 24
Dopamine agonist levodopa





Unified Parkinson’s Disease Rating Scale
Part I 0.7 1.2
Part II 5.6 3.9
Part III 15.7 8.4
Part IV 1.7 2.2
Total 23.7 11.8
Modified Hoehn and Yahr stage 2.1 0.6
Parkinson’s disease Questionnaire-39
Mobility 10.4 9.1
Activities of daily living 5.2 5.1
Emotional well-being 6.0 4.4
Stigma 3.2 2.8
Social support 1.4 1.9
Cognitions 4.0 3.0
Communication 1.7 2.2
Body discomfort 2.5 2.6
Total 34.4 24.2
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